Amsterdam, Gdańsk – August 5, 2025 – Polpharma Biologics S.A. (“Polpharma Biologics”) announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab, an integrin receptor antagonist, (reference product: Entyvio®*), a biologic therapy indicated for moderate to severe ulcerative colitis and...

Amsterdam, Munich – Polpharma Biologics Group BV (“Polpharma Biologics”) and Bioeq AG (“Bioeq”) jointly announce that the Brazilian Health Regulatory Agency (ANVISA) has approved Ranivisio®* (ranibizumab) as a biosimilar to Lucentis®** for the treatment of debilitating retinopathies in Brazil.1 Ranivisio®, developed by Bioeq (a Joint Venture between Polpharma Biologics and Formycon AG) will be exclusively...

In October, together with the Warsaw University of Life Sciences [SGGW], we are launching the new Polpharma Biologics...

Polpharma Biologics at IMPACT CEE

CEBioForum 2024 is an annual international conference for the biotechnology sector and also the largest industry even...

We are expanding our research portfolio - that's what you'll read about in Puls Biznesu. Editor Marcel Zatoński spoke...

Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars,...

Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars,...

Polpharma Biologics announces FDA approval of Tyruko® - first and only approved biosimi...

Polpharma Biologics, an international biotech company dedicated to the development and manufacture of biosimilars, an...